Spots Global Cancer Trial Database for salivary gland squamous cell carcinoma

Every month we try and update this database with for salivary gland squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00639769	Head and Neck C...	cisplatin irinotecan hydr...	18 Years -	Vanderbilt-Ingram Cancer Center
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	NCT00040807	Head and Neck C...	docetaxel irinotecan hydr...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Title XELOX FOR SALIVARY GLAND CANCERS	NCT00101075	Head and Neck C...	Capecitabine Oxaliplatin	18 Years -	Dana-Farber Cancer Institute
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors	NCT00066651	Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton...	SS1(dsFv)-PE38 ...	18 Years -	National Cancer Institute (NCI)
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer	NCT00006107	Head and Neck C...	Taxotere Surgery radiation thera...	18 Years -	Dana-Farber Cancer Institute
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00020189	Head and Neck C... Thromboembolism	acetylsalicylic... alvocidib clopidogrel bis...	18 Years -	National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer	NCT00482872	Head and Neck C...	gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom...	18 Years - 120 Years	Vanderbilt University Medical Center
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00096512	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer	NCT00898664	Head and Neck C...	cytogenetic ana... gene expression... mutation analys... polymerase chai... immunohistochem... laboratory biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases	NCT00062348	Colorectal Canc... Head and Neck C... Metastatic Canc...	boronophenylala... sodium borocapt... conventional su...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer	NCT00049140	Head and Neck C...	EF5 bioluminescence flow cytometry immunohistochem... biopsy	18 Years -	Duke University
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT02035527	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... cisplatin docetaxel Correlative Stu...	18 Years -	Ohio State University Comprehensive Cancer Center
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer	NCT00897793	Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer	venipuncture radiation thera...	18 Years -	Vanderbilt-Ingram Cancer Center
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT00588770	Neck Squamous C... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Neck ... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Recurrent Sinon... Salivary Gland ... Stage IV Hypoph... Stage IV Major ... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Sinon... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Oral ... Stage IVC Oroph... Stage IVC Sinon... Tongue Carcinom...	Bevacizumab Carboplatin Cisplatin Docetaxel Fluorouracil Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer	NCT00049140	Head and Neck C...	EF5 bioluminescence flow cytometry immunohistochem... biopsy	18 Years -	Duke University
Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00898742	Head and Neck C...	DNA and tissue ... reverse transcr... mass spectromet...	-	Vanderbilt-Ingram Cancer Center
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer	NCT00003251	Drug/Agent Toxi... Head and Neck C... Radiation Toxic...	amifostine trih... cisplatin paclitaxel radiation thera...	18 Years -	National Cancer Institute (NCI)
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck	NCT00079053	Head and Neck C...	erlotinib hydro... adjuvant therap...	18 Years - 120 Years	Canadian Cancer Trials Group
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00738868	Head and Neck C...	cetuximab stereotactic bo...	18 Years -	National Cancer Institute (NCI)
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00337129	Head and Neck C...	eribulin mesyla...	18 Years -	National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer	NCT00084435	Head and Neck C...	cisplatin docetaxel radiation thera...	18 Years -	SWOG Cancer Research Network
Radiation Therapy in Treating Patients With Head and Neck Cancer	NCT00021125	Head and Neck C... Non-melanomatou...	adjuvant therap... radiation thera...	-	National Cancer Institute (NCI)
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer	NCT00004163	Head and Neck C...	Trastuzumab	18 Years -	Dana-Farber Cancer Institute
Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy	NCT00898430	Head and Neck C...	DNA Microarray ... MALDI-TOF mass ... DNA microarray ...	-	Vanderbilt-Ingram Cancer Center
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer	NCT00896675	Head and Neck C...	proteomic profi... proteomic profi...	-	Vanderbilt-Ingram Cancer Center
Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer	NCT00899821	Head and Neck C...	aldesleukin recombinant int... sargramostim immunologic tec... biopsy	20 Years - 80 Years	NYU Langone Health
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00639769	Head and Neck C...	cisplatin irinotecan hydr...	18 Years -	Vanderbilt-Ingram Cancer Center
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	NCT01156142	Head and Neck C... Mucositis Oral Complicati... Pain	doxepin hydroch... placebo	18 Years -	Alliance for Clinical Trials in Oncology
Title XELOX FOR SALIVARY GLAND CANCERS	NCT00101075	Head and Neck C...	Capecitabine Oxaliplatin	18 Years -	Dana-Farber Cancer Institute
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00738868	Head and Neck C...	cetuximab stereotactic bo...	18 Years -	National Cancer Institute (NCI)
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer	NCT01313390	Head and Neck C...	docetaxel everolimus laboratory biom... pharmacological...	18 Years -	University College, London
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.	NCT01469429	Metastatic Squa... Salivary Gland ... Stage 0 Hypopha... Stage 0 Larynge... Stage 0 Lip and... Stage 0 Nasopha... Stage 0 Orophar... Stage 0 Paranas... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Nasal... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Oral ... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Oral ... Stage IVC Squam... Paranasal Sinus... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	placebo laboratory biom... questionnaire a... chemoprevention chemoprevention placebo	21 Years -	Ohio State University Comprehensive Cancer Center
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00114283	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	lapatinib ditos... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Validation of a Screening Tool in Geriatric Oncology	NCT00963911	Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Lymphoma Prostate Cancer	Geriatric scree... Multidimensiona...	70 Years - 120 Years	Institut Bergonié
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer	NCT00004163	Head and Neck C...	Trastuzumab	18 Years -	Dana-Farber Cancer Institute
Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer	NCT00482872	Head and Neck C...	gene expression... mutation analys... polymerase chai... polymorphism an... flow cytometry laboratory biom...	18 Years - 120 Years	Vanderbilt University Medical Center
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab	NCT00939627	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	cetuximab placebo sorafenib tosyl... laboratory biom... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer	NCT00896675	Head and Neck C...	proteomic profi... proteomic profi...	-	Vanderbilt-Ingram Cancer Center
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer	NCT02245100	Metastatic Squa... Salivary Gland ... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	Cytology specim... Laboratory biom...	18 Years -	Thomas Jefferson University
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT00906360	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas...	sunitinib malat... pharmacological... 3-dimensional c... cetuximab	18 Years -	National Cancer Institute (NCI)
Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck	NCT00081211	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo...	PV701	18 Years -	National Cancer Institute (NCI)
Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery	NCT00003744	Head and Neck C...	gemcitabine	18 Years -	Dana-Farber Cancer Institute
Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy	NCT00559156	Head and Neck C...	arginine/omega-... cisplatin adjuvant therap... radiation thera...	18 Years -	National Cancer Institute (NCI)
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT00588770	Neck Squamous C... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Neck ... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Recurrent Sinon... Salivary Gland ... Stage IV Hypoph... Stage IV Major ... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Sinon... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Oral ... Stage IVC Oroph... Stage IVC Sinon... Tongue Carcinom...	Bevacizumab Carboplatin Cisplatin Docetaxel Fluorouracil Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer	NCT00084435	Head and Neck C...	cisplatin docetaxel radiation thera...	18 Years -	SWOG Cancer Research Network
Immunotoxin Therapy in Treating Patients With Advanced Cancer	NCT00006981	Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton...	SS1(dsFv)-PE38 ...	18 Years -	National Cancer Institute (NCI)
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer	NCT00003592	Head and Neck C...	methotrexate paclitaxel	18 Years - 120 Years	Eastern Cooperative Oncology Group
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer	NCT01313390	Head and Neck C...	docetaxel everolimus laboratory biom... pharmacological...	18 Years -	University College, London
Family Quality of Life Among Families With a Member Who is a Cancer Patient	NCT00544336	Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Prostate Cancer Solid Tumor	questionnaire a... survey administ... quality-of-life...	21 Years -	Vanderbilt-Ingram Cancer Center
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer	NCT00896675	Head and Neck C...	proteomic profi... proteomic profi...	-	Vanderbilt-Ingram Cancer Center
Title XELOX FOR SALIVARY GLAND CANCERS	NCT00101075	Head and Neck C...	Capecitabine Oxaliplatin	18 Years -	Dana-Farber Cancer Institute
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00507767	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	dasatinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00098631	Metastatic Squa... Recurrent Metas... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Untreated Metas...	lapatinib ditos... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer	NCT00055770	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo...	erlotinib hydro... docetaxel laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Advanced Cancer	NCT00006981	Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton...	SS1(dsFv)-PE38 ...	18 Years -	National Cancer Institute (NCI)
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	NCT00738868	Head and Neck C...	cetuximab stereotactic bo...	18 Years -	National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck	NCT00033618	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	ixabepilone laboratory biom...	18 Years -	National Cancer Institute (NCI)
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection	NCT01249443	HIV Infection Recurrent Anal ... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Recurrent Metas... Recurrent Non-s... Recurrent Ovari... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Anal C... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... Stage IV Non-sm... Stage IV Ovaria... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu...	vorinostat diagnostic labo... pharmacological... carboplatin paclitaxel	18 Years -	AIDS Malignancy Consortium
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00055913	Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo...	bevacizumab erlotinib hydro... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer	NCT00003592	Head and Neck C...	methotrexate paclitaxel	18 Years - 120 Years	Eastern Cooperative Oncology Group
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy	NCT01256385	Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Metas... Recurrent Nasal... Recurrent Nasop... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Salivary Gland ... Squamous Cell C... Stage IV Hypoph... Stage IV Nasoph... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Nasal... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Nasal... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Nasal... Stage IVC Oral ... Stage IVC Oroph... Tongue Carcinom...	Cetuximab Laboratory Biom... Temsirolimus	18 Years -	National Cancer Institute (NCI)
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer	NCT00004163	Head and Neck C...	Trastuzumab	18 Years -	Dana-Farber Cancer Institute
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.	NCT01469429	Metastatic Squa... Salivary Gland ... Stage 0 Hypopha... Stage 0 Larynge... Stage 0 Lip and... Stage 0 Nasopha... Stage 0 Orophar... Stage 0 Paranas... Stage I Salivar... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Squamou... Stage I Verruco... Stage I Verruco... Stage II Saliva... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Squamo... Stage II Verruc... Stage II Verruc... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Nasal... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Oral ... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Oral ... Stage IVC Squam... Paranasal Sinus... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	placebo laboratory biom... questionnaire a... chemoprevention chemoprevention placebo	21 Years -	Ohio State University Comprehensive Cancer Center
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia	NCT00503776	Dysphagia Head and Neck C... Mucositis Xerostomia	exercise interv... amifostine trih... therapeutic die...	21 Years -	Vanderbilt-Ingram Cancer Center
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	NCT01316757	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Tongue Cancer Untreated Metas...	cetuximab paclitaxel carboplatin erlotinib hydro... laboratory biom...	18 Years -	Fox Chase Cancer Center
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel	NCT00003569	Head and Neck C... Lung Cancer Neurotoxicity Ovarian Cancer	cisplatin dimesna paclitaxel	18 Years -	Roswell Park Cancer Institute
Radiation Therapy in Treating Patients With Head and Neck Cancer	NCT00021125	Head and Neck C... Non-melanomatou...	adjuvant therap... radiation thera...	-	National Cancer Institute (NCI)
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer	NCT00049140	Head and Neck C...	EF5 bioluminescence flow cytometry immunohistochem... biopsy	18 Years -	Duke University
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	NCT00337129	Head and Neck C...	eribulin mesyla...	18 Years -	National Cancer Institute (NCI)
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer	NCT01847326	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Tongue Cancer	carboplatin paclitaxel albu... fluorouracil hydroxyurea therapeutic con... radiation thera... hyperfractionat... laboratory biom...	18 Years -	University of Chicago
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00024089	Head and Neck C...	gefitinib	18 Years -	National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00020189	Head and Neck C... Thromboembolism	acetylsalicylic... alvocidib clopidogrel bis...	18 Years -	National Cancer Institute (NCI)
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer	NCT00022217	Head and Neck C...	carboplatin cisplatin-e the... paclitaxel	18 Years -	National Cancer Institute (NCI)
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer	NCT00055770	Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo...	erlotinib hydro... docetaxel laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck	NCT01334177	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IV Saliva... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer	TLR8 agonist VT... cetuximab laboratory biom... pharmacogenomic...	18 Years -	University of Washington
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer	NCT00003264	Head and Neck C...	cisplatin gemcitabine hyd...	18 Years -	Fox Chase Cancer Center
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT00024089	Head and Neck C...	gefitinib	18 Years -	National Cancer Institute (NCI)
Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer	NCT00058006	Head and Neck C... Lung Cancer	celecoxib adjuvant therap...	18 Years -	Northwestern University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: